Documents

A list of downloadable documents created during development.

Diabetes (type 2) - dapagliflozin: Decision Support Unit project specification form

Diabetes (type 2) - dapagliflozin: Decision Support Unit project specification form 19 March 2013 50.7 KB

Diabetes (type 2) - dapagliflozin: appraisal consultation

Diabetes (type 2) - dapagliflozin: appraisal consultation
Diabetes (type 2) - dapagliflozin: appraisal consultation document information
Diabetes (type 2) - dapagliflozin: evaluation report
Diabetes (type 2) - dapagliflozin: pre-briefing meeting 01 February 2013 749.04 KB
Diabetes (type 2) - dapagliflozin: Evidence Review Group report
Diabetes (type 2) - dapagliflozin: Evidence Review Group report 01 February 2013 1.35 MB
Diabetes (type 2) - dapagliflozin: changes to the ERG report 01 February 2013 280.91 KB
Diabetes (type 2) - dapagliflozin: Decision Support Unit report 01 February 2013 875.08 KB
Diabetes (type 2) - dapagliflozin: Evidence Review Group report - factual accuracy check 01 February 2013 117.32 KB
Diabetes (type 2) - dapagliflozin: ERG BMI analyses 01 February 2013 105.25 KB
Diabetes (type 2) - dapagliflozin: manufacturer submission
Diabetes (type 2) - dapagliflozin: Bristol Myers-Squibb and AstraZeneca 01 February 2013 5.56 MB
Diabetes (type 2) - dapagliflozin: Bristol Myers-Squibb and AstraZeneca addendum 01 February 2013 740.56 KB
Diabetes (type 2) - dapagliflozin: clarification
Diabetes (type 2) - dapagliflozin: NICE clarification letter 01 February 2013 101.62 KB
Diabetes (type 2) - dapagliflozin: Manufacturer response to the NICE clarification letter 01 February 2013 958.51 KB
Diabetes (type 2) - dapagliflozin: ERG's additional clarification questions and manufacturer responses 01 February 2013 440.1 KB
Diabetes (type 2) - dapagliflozin: patient group, professional group and NHS organisation submission statements
Diabetes (type 2) - dapagliflozin: Royal College of Nursing 01 February 2013 10.76 KB
Diabetes (type 2) - dapagliflozin: Royal College of Pathologists 01 February 2013 50.68 KB
Diabetes (type 2) - dapagliflozin: NHS Middlesbrough 01 February 2013 56.74 KB
Diabetes (type 2) - dapagliflozin: expert written personal statements
Diabetes (type 2) - dapagliflozin: Kilpatrick Appendix D - clinical specialist statement 01 February 2013 33.47 KB
Diabetes (type 2) - dapagliflozin: Kuti Appendix K - patient/carer expert statement 01 February 2013 213.87 KB
Diabetes (type 2) - dapagliflozin: Linton - Appendix K NHS-Commissioning expert statement declaration 01 February 2013 29.19 KB
Diabetes (type 2) - dapagliflozin: Moulton - Appendix K - Patient/carer expert statement 01 February 2013 105.82 KB
Diabetes (type 2) - dapagliflozin: Ononeze - Appendix K NHS-Commissioning expert statement declaration 01 February 2013 8.57 KB
Diabetes (type 2) - dapagliflozin: Winocour - Appendix D clinical specialist statement 01 February 2013 81.02 KB

Diabetes (type 2) - dapagliflozin: equality impact assessment - scoping

Diabetes (type 2) - dapagliflozin: equality impact assessment - scoping 31 May 2012 32.29 KB

Diabetes (type 2) - dapagliflozin: appendix B - final scope

Diabetes (type 2) - dapagliflozin: appendix B - final scope 25 May 2012 67.02 KB

Diabetes (type 2) - dapagliflozin: appendix C - final matrix

Diabetes (type 2) - dapagliflozin: appendix C - final matrix 25 May 2012 32.86 KB

Diabetes (type 2) - dapagliflozin: appendix D - comments table

Diabetes (type 2) - dapagliflozin: appendix D - comments table 25 May 2012 226.78 KB

Diabetes (type 2) - dapagliflozin [ID427]: appendix A - draft scope for consultation - April 2012

Diabetes (type 2) - dapagliflozin [ID427]: appendix A - draft scope for consultation - April 2012 24 April 2012 77.55 KB

Diabetes (type 2) - dapagliflozin [ID427]: appendix B - provisional matrix - April 2012

Diabetes (type 2) - dapagliflozin [ID427]: appendix B - provisional matrix - April 2012 23 April 2012 38.58 KB

Diabetes (type 2) - dapagliflozin [ID427]: appendix B - draft scope for consultation (pre-referral) - May 2011

Diabetes (type 2) - dapagliflozin [ID427]: appendix B - draft scope for consultation (pre-referral) - May 2011 24 April 2012 67.99 KB

Diabetes (type 2) - dapagliflozin [ID427]: appendix C - provisional matrix (pre-referral) - May 2011

Diabetes (type 2) - dapagliflozin [ID427]: appendix C - provisional matrix (pre-referral) - May 2011 24 April 2012 36.46 KB

Dapagliflozin in combination therapy for treating type 2 diabetes

Review proposal consultation

Review proposal consultation

Stakeholder matrix 26 February 2016 97.52 KB

Review proposal paper 26 February 2016 212.62 KB

Diabetes (type 2) ? dapagliflozin: equality impact assessment - guidance review

Diabetes (type 2) - dapagliflozin: equality impact assessment - scoping 31 May 2012 32.29 KB

Diabetes (type 2) - dapagliflozin: final appraisal determination

Diabetes (type 2) - dapagliflozin: final appraisal determination information

Diabetes (type 2) - dapagliflozin: final appraisal determination document 30 May 2013 479.84 KB

Diabetes (type 2) - dapagliflozin: evaluation report information

Diabetes (type 2) - dapagliflozin: evaluation report 30 May 2013 4.49 MB

Diabetes (type 2) - dapagliflozin: Decision Support Unit project specification form

Diabetes (type 2) - dapagliflozin: Decision Support Unit project specification form 19 March 2013 50.7 KB

Diabetes (type 2) - dapagliflozin: appraisal consultation

Diabetes (type 2) - dapagliflozin: appraisal consultation

Diabetes (type 2) - dapagliflozin: appraisal consultation document information

Diabetes (type 2) - dapagliflozin: evaluation report

Diabetes (type 2) - dapagliflozin: pre-briefing meeting 01 February 2013 749.04 KB

Diabetes (type 2) - dapagliflozin: Evidence Review Group report

Diabetes (type 2) - dapagliflozin: Evidence Review Group report 01 February 2013 1.35 MB

Diabetes (type 2) - dapagliflozin: changes to the ERG report 01 February 2013 280.91 KB

Diabetes (type 2) - dapagliflozin: Decision Support Unit report 01 February 2013 875.08 KB

Diabetes (type 2) - dapagliflozin: Evidence Review Group report - factual accuracy check 01 February 2013 117.32 KB

Diabetes (type 2) - dapagliflozin: ERG BMI analyses 01 February 2013 105.25 KB

Diabetes (type 2) - dapagliflozin: manufacturer submission

Diabetes (type 2) - dapagliflozin: Bristol Myers-Squibb and AstraZeneca 01 February 2013 5.56 MB

Diabetes (type 2) - dapagliflozin: Bristol Myers-Squibb and AstraZeneca addendum 01 February 2013 740.56 KB

Diabetes (type 2) - dapagliflozin: clarification

Diabetes (type 2) - dapagliflozin: NICE clarification letter 01 February 2013 101.62 KB

Diabetes (type 2) - dapagliflozin: Manufacturer response to the NICE clarification letter 01 February 2013 958.51 KB

Diabetes (type 2) - dapagliflozin: ERG's additional clarification questions and manufacturer responses 01 February 2013 440.1 KB

Diabetes (type 2) - dapagliflozin: patient group, professional group and NHS organisation submission statements

Diabetes (type 2) - dapagliflozin: Royal College of Nursing 01 February 2013 10.76 KB

Diabetes (type 2) - dapagliflozin: Royal College of Pathologists 01 February 2013 50.68 KB

Diabetes (type 2) - dapagliflozin: NHS Middlesbrough 01 February 2013 56.74 KB

Diabetes (type 2) - dapagliflozin: expert written personal statements

Diabetes (type 2) - dapagliflozin: Kilpatrick Appendix D - clinical specialist statement 01 February 2013 33.47 KB

Diabetes (type 2) - dapagliflozin: Kuti Appendix K - patient/carer expert statement 01 February 2013 213.87 KB

Diabetes (type 2) - dapagliflozin: Linton - Appendix K NHS-Commissioning expert statement declaration 01 February 2013 29.19 KB

Diabetes (type 2) - dapagliflozin: Moulton - Appendix K - Patient/carer expert statement 01 February 2013 105.82 KB

Diabetes (type 2) - dapagliflozin: Ononeze - Appendix K NHS-Commissioning expert statement declaration 01 February 2013 8.57 KB

Diabetes (type 2) - dapagliflozin: Winocour - Appendix D clinical specialist statement 01 February 2013 81.02 KB

Diabetes (type 2) - dapagliflozin: equality impact assessment - scoping

Diabetes (type 2) - dapagliflozin: equality impact assessment - scoping 31 May 2012 32.29 KB

Diabetes (type 2) - dapagliflozin: appendix B - final scope

Diabetes (type 2) - dapagliflozin: appendix B - final scope 25 May 2012 67.02 KB

Diabetes (type 2) - dapagliflozin: appendix C - final matrix

Diabetes (type 2) - dapagliflozin: appendix C - final matrix 25 May 2012 32.86 KB

Diabetes (type 2) - dapagliflozin: appendix D - comments table

Diabetes (type 2) - dapagliflozin: appendix D - comments table 25 May 2012 226.78 KB

Diabetes (type 2) - dapagliflozin [ID427]: appendix A - draft scope for consultation - April 2012

Diabetes (type 2) - dapagliflozin [ID427]: appendix A - draft scope for consultation - April 2012 24 April 2012 77.55 KB

Diabetes (type 2) - dapagliflozin [ID427]: appendix B - provisional matrix - April 2012

Diabetes (type 2) - dapagliflozin [ID427]: appendix B - provisional matrix - April 2012 23 April 2012 38.58 KB

Diabetes (type 2) - dapagliflozin [ID427]: appendix B - draft scope for consultation (pre-referral) - May 2011

Diabetes (type 2) - dapagliflozin [ID427]: appendix B - draft scope for consultation (pre-referral) - May 2011 24 April 2012 67.99 KB

Diabetes (type 2) - dapagliflozin [ID427]: appendix C - provisional matrix (pre-referral) - May 2011

Diabetes (type 2) - dapagliflozin [ID427]: appendix C - provisional matrix (pre-referral) - May 2011 24 April 2012 36.46 KB